Alain G. Zeimet — Endo Lab

case-report 2025

Are brain metastases a special issue in POLE-mutated endometrial cancer? a case report series

Frontiers in oncology ·doi:10.3389/fonc.2025.1568137

POLE-mutated endometrial cancers have repeatedly shown to harbor an excellent prognosis. Recurrences or primary advanced disease are rare events in this subgroup. We report three cases of POLE-mutated endometrioid ECs with brain metastases.…

observational 2020

High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome

International journal of cancer ·doi:10.1002/ijc.32818

Ovarian cancer (OC) is the most lethal gynecological malignancy, with platinum-based chemotherapy remaining the mainstay for adjuvant treatment after surgery. The lack of indication for immunotherapy may at least in part result from the lac…

case-report 2013

Endometroid carcinoma developing in endometriosis over the symphysis pubis

Gynecologic oncology case reports ·doi:10.1016/j.gynor.2013.08.001

•We present the case of a premenopausal woman, who developed an endometriosis based endometrial carcinoma at the mons pubis.•After a three year follow-up period the patient remains disease free.

other 2005

Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions

Gynecologic Oncology ·doi:10.1016/j.ygyno.2005.02.017

OBJECTIVE: Inflammatory or malignant peritoneal diseases are associated with high levels of ascitic vascular endothelial growth factor (VEGF). We compared the VEGF secretion by human peritoneal mesothelial cells (HPMC) and ovarian carcinoma…